Most content about kratom strains is written to help people choose a product. This piece is not that. It's written for people who have been using kratom for months or years and want to understand what their strain history means for how withdrawal works and how cessation should be approached.
If you're researching strains to buy, this article won't be useful to you. If you're trying to understand why your withdrawal profile differs from what you've read about other people's, or whether your strain history matters for how you taper, you're in the right place.
TL;DR: Red, green, and white vein kratom have meaningfully different alkaloid profiles that affect both their effects during use and the character of withdrawal when stopping. Red vein strains have the highest 7-hydroxymitragynine (7-OH) content and the most opioid-receptor-dominant effects; red-vein users typically experience the most opioid-like withdrawal. White vein strains have more stimulant-adjacent alkaloids and lower 7-OH; white-vein users may experience more anxiety-dominant, energy-disrupted withdrawal. Green is intermediate. Extracts override strain differences — extract withdrawal is uniformly opioid-heavy regardless of the underlying leaf color. None of this changes the fundamental recovery process, but it helps explain why people's withdrawal experiences differ.
What the vein color actually refers to
The color designation — red, green, or white — refers to the color of the central leaf vein and stem of the Mitragyna speciosa plant at the time of harvest. This corresponds to maturity: white-vein leaves are harvested earliest (immature), green-vein leaves at a middle stage, and red-vein leaves when fully mature.
Maturation stage affects alkaloid expression, though the relationship is more variable than marketing materials suggest. Commercial kratom's alkaloid content also varies by growing region, soil conditions, drying method, and vendor processing. Two "red Bali" products from different vendors may have significantly different alkaloid profiles. This caveat matters for understanding the limits of generalizations about strains.
With that caveat stated: the population-level differences in alkaloid profiles across vein colors are real and clinically meaningful.
The alkaloid differences that matter for recovery
The two alkaloids most relevant to dependency and withdrawal are mitragynine (the primary alkaloid by volume in all kratom) and 7-hydroxymitragynine (7-OH) (the more potent opioid-active metabolite).
Red vein: Consistently shows higher 7-OH content relative to green and white vein in multiple analytical studies (Ramanathan & McCurdy, 2018; Prevete et al., 2022). The higher 7-OH concentration corresponds to stronger mu-opioid receptor activation — which means more sedating, more pain-relieving effects during use, and more opioid-receptor-dependent withdrawal when stopping. Red vein is the most commonly used for chronic pain and sleep, which are the conditions most likely to produce heavy daily use patterns.
White vein: Lower 7-OH relative to other strains. Higher relative concentrations of mitragynine and certain minor alkaloids associated with stimulant effects, including some adrenergic activity. Used primarily for energy, focus, and mood at lower doses. The dependency that develops is still real — mitragynine is still a mu-opioid partial agonist even at lower 7-OH ratios — but the withdrawal character tends to be less opioid-like and more anxiety/energy-disrupted.
Green vein: Intermediate alkaloid profile between red and white. Used for a combination of pain relief, anxiety reduction, and energy. Withdrawal is typically intermediate — some opioid-like elements, some stimulant-withdrawal character.
How strain history affects withdrawal character
When someone stops kratom, the withdrawal character reflects the receptor systems that adapted to the specific alkaloid profile they were exposed to.
Red-vein heavy users stopping abruptly experience withdrawal that most resembles opioid withdrawal: significant muscle aches, GI disturbance, chills, sweating, and pronounced anxiety and insomnia. The mu-opioid receptor dependence is the dominant factor. For people who have used red vein exclusively at high doses for years, acute withdrawal can be severe.
White-vein heavy users stopping abruptly typically experience less opioid-like physical withdrawal but more prominent anxiety, irritability, energy disruption, and difficulty concentrating. The stimulant-adjacent withdrawal character comes from the adrenergic and dopaminergic activity of the alkaloid profile. Sleep is still disrupted, but the mechanism is more anxiety-driven than opioid-receptor-driven.
Green-vein users experience a mix — often described as "the physical but not as bad, the anxiety and energy piece is the hard part."
Practical implication for tapering: If you've been on red vein primarily, your taper is fundamentally about managing mu-opioid receptor readjustment. The symptom cluster — aches, GI, sweating — responds to the interventions that help opioid withdrawal (hydration, electrolytes, loperamide for GI at appropriate doses, movement). If you've been on white vein primarily, the taper symptom cluster skews toward anxiety and sleep disruption — L-theanine, consistent sleep scheduling, and exercise are the most relevant supports.
Strain rotation and tolerance
Strain rotation — alternating between strains in an attempt to prevent tolerance — is commonly discussed in kratom communities. It's worth understanding why it doesn't reliably work.
Tolerance to kratom develops at multiple levels: receptor-level (mu-opioid receptor downregulation), metabolic tolerance (upregulation of the CYP450 enzymes that process mitragynine), and psychological tolerance (habituation to effects). Switching strains changes the alkaloid ratio but doesn't reset the receptors or the metabolic tolerance. The receptors have adapted to mitragynine generally, not to a specific strain's ratio.
In practice, strain rotation often accelerates total alkaloid exposure and tolerance because users experiencing diminished effects from rotation cycles tend to increase their doses to compensate. The net effect is frequently a higher baseline dose than if they'd stayed on a single strain.
What this means if you're currently on a high-7-OH product
If your primary kratom use has been red-vein leaf at high doses, or any extract product (which concentrates 7-OH regardless of vein color), your withdrawal will have the most opioid-receptor-intensive character. The most practical implications:
On taper approach: A slower taper with more conservative reductions (10% per 2 weeks rather than 10% per week) tends to be more tolerable for heavy red-vein or extract users. The receptor adaptation is deeper and takes longer to adjust.
On switching products for taper: Some people switch from red vein to green vein midway through a taper, seeking a gentler final stretch. This can be effective for the opioid-like symptom cluster, but it introduces a new alkaloid ratio the body must adjust to. There's no consensus on whether this helps or hinders; it's a decision worth discussing with a prescriber if you're doing a supervised taper.
On the extract-to-leaf switch: If you've been using extracts, switching to equivalent plain-leaf doses before beginning a dose taper is the recommended first step — extracts make accurate dose management difficult, and the concentrated 7-OH profile makes the taper harder to control. This switch itself may produce a mild adjustment period as 7-OH exposure drops.
The variable that overrides strain: extract use
It's worth stating clearly: if you have been using extract products — concentrated kratom shots, high-potency capsules, MIT 45, OPMS, or similar — your strain history matters less than your extract history. Extracts concentrate mitragynine and its 7-OH metabolic pathway regardless of vein color. The withdrawal profile of extract users, regardless of whether the underlying leaf was red, green, or white, skews toward the most opioid-receptor-intensive end of the spectrum.
For a deeper look at extract pharmacology and why it matters for cessation, see our article on kratom leaf vs. extract vs. 7-OH.
Getting support
If you're planning cessation and want clinical input on your specific strain and dose history, findtreatment.gov (SAMHSA's treatment locator) lists addiction medicine providers by location. Telehealth options are available.
Our kratom taper schedule article provides a framework for the reduction process. For understanding the timeline of withdrawal after the last dose, see our kratom withdrawal timeline.
Coach Aria is a 12-week behavioral coaching program for kratom recovery. Built for the pharmacological reality of kratom — not borrowed from opioid or stimulant recovery frameworks that don't fit.